Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) has an increasing prevalence, morbidity, and mortality both within the United States and globally. Here, we review newer evidence demonstrating racial and ethnic disparities that exist in the incidence of MASLD in the United States Many studies demonstrate that Hispanic populations have the highest prevalence of MASLD within the United States, followed by non-Hispanic White populations and then non-Hispanic Black populations. In addition, we present the latest research investigating specific factors that contribute to these disparities, including genetics, environmental exposures, diet, physical activity, and socioeconomic disparities. Finally, we discuss future directions and interventions needed to increase knowledge of racial and ethnic disparities in MASLD and reduce future disparities. The necessary strategies include increasing diversity and documentation of race and ethnicity in MASLD clinical studies, and increased screening and preventative health education for MASLD in vulnerable populations.

Keywords

Metabolic / fatty liver disease / non-alcoholic / racial / ethnic / disparities

References

[1] Rinella ME,Ratziu V.NAFLD Nomenclature consensus groupA multisociety Delphi consensus statement on new fatty liver disease nomenclature.Hepatology2023;78:1966-86 PMCID:PMC10653297

[2] Iqbal U,Akhtar D,Ahmed A.The epidemiology, risk profiling and diagnostic challenges of nonalcoholic fatty liver disease.Medicines2019;6:41 PMCID:PMC6473603

[3] Younossi ZM,Anstee QM.The global burden of liver disease.Clin Gastroenterol Hepatol2023;21:1978-91

[4] Kumar R,Anand U.Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations.J Clin Transl Hepatol2020;8:76-86 PMCID:PMC7132013

[5] Li W,Quek J.The growing prevalence of nonalcoholic fatty liver disease (NAFLD), determined by fatty liver index, amongst young adults in the United States. A 20-year experience.Metab Target Organ Damage2022;2:19

[6] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[7] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2024;80:e76-7

[8] Nasr P,Ekstedt M.Non-metabolic causes of steatotic liver disease.Metab Target Organ Damage2023;3:19

[9] Song SJ,Wong GL,Yip TC.Can we use old NAFLD data under the new MASLD definition?.J Hepatol2024;80:e54-6

[10] Patel P,Paul S.Racial disparities in nonalcoholic fatty liver disease clinical trial enrollment: A systematic review and meta-analysis.World J Hepatol2020;12:506-18 PMCID:PMC7475777

[11] Jennings J,Yao MD.NAFLD-NASH: An under-recognized epidemic.Curr Vasc Pharmacol2018;16:209-13

[12] Thandra KC,Saginala K,Rawla P.Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression.Clin Exp Hepatol2020;6:289-94 PMCID:PMC7816638

[13] Browning JD,Dobbins R.Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.Hepatology2004;40:1387-95

[14] Rich NE,Mufti AR.Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis.Clin Gastroenterol Hepatol2018;16:198-210.e2 PMCID:PMC5794571

[15] Talens M,Lazarus JV,Pericàs JM.What do we know about inequalities in NAFLD distribution and outcomes? A scoping review.J Clin Med2021;10:5019 PMCID:PMC8584385

[16] Bambha K,Abraham M.Nonalcoholic Steatohepatitis Clinical Research Network Research GroupEthnicity and nonalcoholic fatty liver disease.Hepatology2012;55:769-80 PMCID:PMC3278533

[17] Cullen MR,Russo LJ,Ababio Y.Disease-specific health disparities: a targeted review focusing on race and ethnicity.Healthcare2022;10:603 PMCID:PMC9025451

[18] Adejumo AC,Adegbala OM.Prevalence, trends, outcomes, and disparities in hospitalizations for nonalcoholic fatty liver disease in the United States.Ann Gastroenterol2019;32:504-13 PMCID:PMC6686099

[19] Le MH,Cheung R,Nguyen MH.Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016.J Intern Med2020;287:711-22

[20] Shaheen M,Tedlos M,Najjar SM.Racial/ethnic and gender disparity in the severity of NAFLD among people with diabetes or prediabetes.Front Physiol2023;14:1076730 PMCID:PMC9986441

[21] Arshad T,Biswas R,Henry L.Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016.Hepatol Commun2021;5:1676-88 PMCID:PMC8485885

[22] Botero P,Jimenez MC,Messiah SE.Predictors of non-alcoholic liver disease in ethnically diverse overweight children and adolescents.Curr Pediatr Rev2018;14:130-5

[23] Fernandes DM,Azam M.Pediatric nonalcoholic fatty liver disease in New York city: an autopsy study.J Pediatr2018;200:174-80

[24] Dybbro E,Salihu HM.Trends and disparities in pediatric nonalcoholic fatty liver disease-associated hospitalizations in the United States.J Pediatr Gastroenterol Nutr2022;74:503-9

[25] Browning MG,DeAntonio JH.Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes.Int J Obes2018;42:926-9

[26] Mahabaleshwarkar R,McKillop IH.The association between metabolic syndrome and non-alcoholic fatty liver disease diagnosis varies by race.Metab Syndr Relat Disord2022;20:286-94

[27] Bril F,Liu IC,Dayton K.Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients.Diabetes Care2018;41:187-92

[28] Golabi P,Hwang JP,Lee HM.Prevalence and outcomes of non-alcoholic fatty liver disease (NAFLD) among Asian American adults in the United States.Liver Int2019;39:748-57

[29] Barritt AS,Gitlin N.Patient determinants for histologic diagnosis of NAFLD in the real world: A TARGET-NASH study.Hepatol Commun2021;5:938-46 PMCID:PMC8183178

[30] Lomonaco R,Orsak B.Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.Hepatology2012;55:1389-97

[31] Ha J,Avirineni A.Burden of hepatocellular carcinoma among Hispanics in South Texas: a systematic review.Biomark Res2017;5:15 PMCID:PMC5399820

[32] Zarrinpar A,Agopian VG.Metabolic factors affecting hepatocellular carcinoma in steatohepatitis.Liver Int2019;39:531-9 PMCID:PMC6617514

[33] Chang ET,Alfaro-Velcamp T,Glaser SL.Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians.Cancer Epidemiol Biomarkers Prev2010;19:3106-18 PMCID:PMC3005535

[34] Sajja KC,Rockey DC.Age and ethnicity in cirrhosis.J Investig Med2014;62:920-6 PMCID:PMC4172494

[35] Qayed E,Jagannathan R,Pasquel FJ.Characteristics and outcomes of black and white patients hospitalized with nonalcoholic steatohepatitis: a nationwide analysis.J Clin Gastroenterol2023;57:508-14

[36] Couto CA,Calmet F,Levy C.Effect of ethnicity on liver transplant for hepatocellular carcinoma.Exp Clin Transplant2013;11:339-45

[37] Villalón A,Fuentes-lópez E.Colorectal adenomas and MAFLD: a cross-sectional study in a Hispanic screening cohort.Metab Target Organ Damage2022;2:3

[38] Balakrishnan M,Cortes-Santiago N.External validation of four point-of-care noninvasive scores for predicting advanced hepatic fibrosis in a predominantly Hispanic NAFLD population.Dig Dis Sci2021;66:2387-93

[39] De Silva S,Kemos P.Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent.Frontline Gastroenterol2018;9:115-21 PMCID:PMC5868450

[40] Mitsche MA,Cohen JC.Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets.J Biol Chem2018;293:9232 PMCID:PMC6005448

[41] Luukkonen PK,Hölttä-Vuori M.Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids.JCI Insight2019;4:127902 PMCID:PMC6777808

[42] Romeo S,Xing C.Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.Nat Genet2008;40:1461-5 PMCID:PMC2597056

[43] Auton A,Durbin RM.1000 Genomes Project ConsortiumA global reference for human genetic variation.Nature2015;526:68-74 PMCID:PMC4750478

[44] Roe JD,Klimentidis YC.Association of PNPLA3 I148M with liver disease biomarkers in latinos.Hum Hered2021;86:21-7

[45] Rutledge SM,Ma N.Association of HSD17B13 and PNPLA3 with liver enzymes and fibrosis in Hispanic/latino individuals of diverse genetic ancestries.Clin Gastroenterol Hepatol2023;21:2578-87.e11

[46] Young KA,Fingerlin TE.Genome-wide association study identifies loci for liver enzyme concentrations in Mexican Americans: The guardian consortium.Obesity2019;27:1331-7 PMCID:PMC6656610

[47] Walker RW,Sorokin EP.A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank.J Hepatol2020;72:1070-81 PMCID:PMC7840172

[48] Kallwitz ER,Kuniholm MH.American ancestry is a risk factor for suspected nonalcoholic fatty liver disease in Hispanic/latino adults.Clin Gastroenterol Hepatol2019;17:2301-9

[49] Wang J,Bogumil D.Association of genetic risk score with NAFLD in an ethnically diverse cohort.Hepatol Commun2021;5:1689-703 PMCID:PMC8485887

[50] Kallwitz E,Kuniholm MH.Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.Liver Int2020;40:889-93

[51] Jiao J,Sabotta CM.Circulating fatty acids associated with advanced liver fibrosis and hepatocellular carcinoma in South Texas Hispanics.Cancer Epidemiol Biomarkers Prev2021;30:1643-51 PMCID:PMC8419070

[52] Mazi TA,Fiehn O.Plasma oxylipin profile discriminates ethnicities in subjects with non-alcoholic steatohepatitis: an exploratory analysis.Metabolites2022;12:192 PMCID:PMC8875408

[53] Mazi TA,Newman JW.Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study.Free Radic Biol Med2021;172:490-502 PMCID:PMC8712226

[54] Rausch JC,Chalasani N.NASH Clinical Research NetworkGenetic variants associated with obesity and insulin resistance in Hispanic boys with nonalcoholic fatty liver disease.J Pediatr Gastroenterol Nutr2018;66:789-96 PMCID:PMC5916321

[55] Umano GR,Di Sessa A.The rs626283 variant in the MBOAT7 gene is associated with insulin resistance and fatty liver in caucasian obese youth.Am J Gastroenterol2018;113:376-83

[56] Nichols PH,May B.Effect of TSH on non-alcoholic fatty liver disease (NAFLD) independent of obesity in children of predominantly Hispanic/Latino ancestry by causal mediation analysis.PLoS One2020;15:e0234985 PMCID:PMC7307750

[57] Wu H,Kinnear D,Quintanilla NM.Clinical, laboratory, and histologic correlates of serum antinuclear antibody in Hispanic pediatric patients with nonalcoholic fatty liver disease.Am J Clin Pathol2022;158:221-7

[58] Frediani JK,Vos MB,Marsit CJ.Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among United States adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014.Environ Health2018;17:6 PMCID:PMC5769436

[59] Verstraete SG,Perito ER.Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003-2010.Environ Health2018;17:12 PMCID:PMC5796302

[60] Chen R,Xu C.Associations between mercury exposure and the risk of nonalcoholic fatty liver disease (NAFLD) in US adolescents.Environ Sci Pollut Res Int2019;26:31384-91

[61] Han S,Lee S,Han HJ.Serum cadmium is associated with hepatic steatosis and fibrosis: Korean national health and nutrition examination survey data IV-VII.Medicine2022;101:e28559 PMCID:PMC8797563

[62] Jones DH,Guo Q,Jia C.Racial disparities in the heavy metal contamination of urban soil in the Southeastern United States.Int J Environ Res Public Health2022;19:1105 PMCID:PMC8834334

[63] Angulo P.Nonalcoholic fatty liver disease.N Engl J Med2002;346:1221-31

[64] Juanola O,Francés R.Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors.Int J Environ Res Public Health2021;18:5227 PMCID:PMC8155932

[65] Williams CD,Asike MI.Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.Gastroenterology2011;140:124-31

[66] Ryu S,Jung HS.Relationship of sitting time and physical activity with non-alcoholic fatty liver disease.J Hepatol2015;63:1229-PMID: 26385766 DOI: 10.1016/j.jhep.2015.07.010 37

[67] Caviglia GP,Fagoonee S,Pellicano R.Liver fibrosis: the 2017 state of art.Panminerva Med2017;59:320-31

[68] Mota M,Cazanave SC.Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.Metabolism2016;65:1049-61 PMCID:PMC4931958

[69] Chen H,Li Z.Consumption of sugar-sweetened beverages has a dose-dependent effect on the risk of non-alcoholic fatty liver disease: an updated systematic review and dose-response meta-analysis.Int J Environ Res Public Health2019;16:2192 PMCID:PMC6617076

[70] Baratta F,Polimeni L.Adherence to mediterranean diet and non-alcoholic fatty liver disease: effect on insulin resistance.Am J Gastroenterol2017;112:1832-9

[71] Kim D,Li AA,Ahmed A.Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease.Hepatology2020;72:1556-68

[72] Heredia NI,Balakrishnan M.Physical activity and diet quality in relation to non-alcoholic fatty liver disease: A cross-sectional study in a representative sample of United States adults using NHANES 2017-2018.Prev Med2022;154:106903 PMCID:PMC8724407

[73] Heredia NI,Balakrishnan M,Thrift AP.Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the United States .Ethn Health2023;28:299-312 PMCID:PMC9307692

[74] Helajärvi H,Heinonen OJ.Television viewing and fatty liver in early midlife. The cardiovascular risk in young finns study.Ann Med2015;47:519-26

[75] Meng G,Fang L.The overall computer/mobile devices usage time is related to newly diagnosed non-alcoholic fatty liver disease: a population-based study.Ann Med2016;48:568-76

[76] Semmler G,Reiberger T.Diet and exercise in NAFLD/NASH: Beyond the obvious.Liver Int2021;41:2249-68 PMCID:PMC9292198

[77] Wegermann K,Mavis AM,Diehl AM.Tackling nonalcoholic fatty liver disease: three targeted populations.Hepatology2021;73:1199-206

[78] Baker PR 2nd.Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.J Clin Invest2018;128:3692-703 PMCID:PMC6118579

[79] Hollingsworth DR,Yamamoto TR.Diabetes in pregnancy in Mexican Americans.Diabetes Care1991;14:695-705

[80] Ogden CL,Carroll MD.Obesity and socioeconomic status in children and adolescents: United States, 2005-2008.NCHS Data Brief2010;51:1-8

[81] López-Cevallos DF,Bethel JW.Is there a link between wealth and cardiovascular disease risk factors among Hispanic/Latinos? Results from the HCHS/SOL sociocultural ancillary study.Ethn Health2018;23:902-13 PMCID:PMC5796865

[82] Giammarino AM,Bulsara K.Community socioeconomic deprivation predicts nonalcoholic steatohepatitis.Hepatol Commun2022;6:550-60 PMCID:PMC8870017

[83] Elangovan A,Smith ZL.Pharmacotherapy for obesity-trends using a population level national database.Obes Surg2021;31:1105-12

[84] May M,Engeli S.Modern pharmacological treatment of obese patients.Ther Adv Endocrinol Metab2020;11:2042018819897527 PMCID:PMC6977225